½ÃÀ庸°í¼­
»óǰÄÚµå
1358036

Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå : ¹ßÇö ½Ã½ºÅÛº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Custom Recombinant Protein Production Services Market, By Expression System, By End User, By Region

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀåÀº 2023³â¿¡´Â 49¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2023-2030³â)¿¡´Â 11.5%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ´ë»ó ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 49¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ CAGR 11.50% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 105¾ï ´Þ·¯
¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå Á¡À¯À²(%), ¹ßÇö°èº°, 2023³â
Custom Recombinant Protein Production Services Market-IMG1

ÀçÁ¶ÇÕ ´Ü¹éÁúÀº »ý¸í°øÇÐ, ¿¬±¸ ¹× ÀÇ·á ºÐ¾ß¿¡¼­ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»êÀº »ý¸í°úÇÐ ºÐ¾ß¿¡¼­ »ç¿ëµÇ´Â È¿À²ÀûÀÎ ±â¼ú Áß ÇϳªÀ̸ç, ÷´Ü ÀÇ·á ºÐ¾ß¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ ´Ü¹éÁúÀº ƯÁ¤ ±â¼úÀ» »ç¿ëÇÏ¿© ´Ü¹éÁúÀ» Á¶ÀÛÇÏ¿© °³¹ßµË´Ï´Ù. ÀÌÈÄ À¯ÀüÀÚ´Â ÀÌ·¯ÇÑ ÀçÁ¶ÇÕ ´Ü¹éÁúÀ» ¾ÏȣȭÇÏ´Â µ¥ »ç¿ëµÇ¸ç, ´ë·®À¸·Î »ý»êµÇ¾î Ä¡·áÁ¦¿Í »ó¾÷¿ë Á¦Ç° »ý»ê¿¡ »ç¿ëµË´Ï´Ù. »ý¸í°úÇÐ ºÐ¾ß¿¡ ´ëÇÑ Á¤ºÎÀÇ ±¸»ó°ú ÀÚ±Ý Áö¿ø Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁúÀÇ ´ëºÎºÐÀº ÁøÇÙ»ý¹°, È¿¸ð, Æ÷À¯·ù, °ïÃæ ¼¼Æ÷ ¹è¾ç ½Ã½ºÅÛ¿¡¼­¸¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ±Û¸®ÄÚ½ÇÈ­¿Í °°Àº ¹ø¿ª ÈÄ º¯ÇüÀÌ ÇÊ¿äÇϰí Á¦°øµË´Ï´Ù. ÀϽÃÀûÀÎ ´Ü¹éÁú »ý»ê¿¡´Â HEK293 À¯·¡ ¼¼Æ÷ÁÖ°¡ »ç¿ëµË´Ï´Ù. ÇöÀç ´ëºÎºÐÀÇ ÀçÁ¶ÇÕ Ä¡·á¿ë ´Ü¹éÁúÀº ÀÚ¿¬°ú À¯»çÇÑ °íǰÁúÀÇ ´Ü¹éÁúÀ» »ý»êÇÒ ¼ö ÀÖ´Â Æ÷À¯·ù ¼¼Æ÷¿¡¼­ »ý»êµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¹Àº ½ÂÀÎµÈ ÀçÁ¶ÇÕ Ä¡·á¿ë ´Ü¹éÁúÀº À¯ÀüÇÐÀûÀ¸·Î Àß Æ¯¼ºÈ­µÇ¾î ÀÖ°í, ºü¸£°Ô Áõ½ÄÇϸç, ³ôÀº ¼öÀ²·Î »ý»êÇÒ ¼ö ÀÖÀ¸¹Ç·Î ´ëÀå±Õ¿¡¼­ »ý»êµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÁÖ¿ä ±â¾÷ÀÇ Àμö¿Í °°Àº ¹«±âÀû ¼ºÀå Àü·«ÀÇ Ã¤Åà Áõ°¡´Â ¿¹Ãø ±â°£ Áß ºÎ¹® ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 7¿ù, °íµµ·Î °ËÁõµÈ 1Â÷ Ç×ü Á¦Á¶¾÷üÀÎ Atlas Antibodies´Â Áß±¹ ÇܽºÅÍ ³­¼Ò(CHO) ¼¼Æ÷¿¡¼­ ÀϽÃÀûÀÎ ÀçÁ¶ÇÕ Ç×ü ¹ßÇöÀ» °³¹ßÇÏ´Â Evitria¸¦ ÀμöÇß½À´Ï´Ù.(RTP) »ý»ê¿¡ ÀûÇÕÇÑ ¹ßÇö ½Ã½ºÅÛÀÔ´Ï´Ù. À̹ø Àμö¸¦ ÅëÇØ ¾ç»çÀÇ Ç×ü ¼Ö·ç¼ÇÀÌ À¶ÇÕµÇ¾î »ç¾÷ÀÌ È®´ëµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀåÀ» »ó¼¼ ºÐ¼®Çϰí, 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð ¹× CAGRÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¼³¸íÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ¼³¸íÇϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã³ª ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±â¹ÝÇÏ¿© ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
  • º» ¸®Æ÷Æ®·ÎºÎÅÍÀÇ ÀλçÀÌÆ®´Â ¸¶ÄÉÆÃ ´ã´çÀÚ³ª ±â¾÷ÀÇ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÏ´Â °ÍÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
  • ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå ¸®Æ÷Æ®´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©¾÷ü, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡°Ô ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»çÀÇ ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÃÖ±Ù Å×½ºÆ® ¹ß»ç
  • ¿ªÇÐ
  • ÇÕº´, Àμö ¹× Çù¾÷
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÁÖ¿ä ¹ßÀü
  • PEST ºÐ¼®

Á¦4Àå ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå, ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º(COVID-19)ÀÇ ¿µÇ⠺м®

  • °æÁ¦Àû ¿µÇâ
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º(COVID-19)ÀÇ ¿ªÇÐ
  • ¼ö¿ä¿Í °ø±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå, ¹ßÇö ½Ã½ºÅÛº°, 2018-2030³â

  • Æ÷À¯·ù
  • ¼¼±Õ
  • °ïÃæ
  • È¿¸ð
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â

  • Á¶»ç±â°ü
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷°ú Á¦¾àȸ»ç
  • ÀÓ»ó½ÃÇè¼öʱâ°ü
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê ¼­ºñ½º ½ÃÀå, Áö¿ªº°, 2018-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • GenScript Biotech Corporation
    • SignalChem Biotech Inc.
    • Crown Bioscience, Inc.
    • BPS Bioscience Inc.
    • Novoprotein
    • Applied Biological Materials(abm) Inc.
    • Eurofins Pharma Discovery Services
    • Abgent(WuXi AppTec Company)
    • Kempbio, Inc.
    • Trenzyme GmbH
    • Sino Biological Inc.
    • Aragen Bioscience, a GVKBIO Company
    • LakePharma, Inc.
    • Proteos Inc.
    • Icosagen AS
    • Novus Biological LLC
    • Proteogenix
    • Premas Biotech
    • ATUM
    • Aldevron

Á¦9Àå ¼½¼Ç

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
  • Coherent Market Insights ¼Ò°³¿Í ¹®ÀÇ
KSA 23.10.25

The global custom recombinant protein production services market is estimated to be valued at US$ 4.9 billion in 2023 and is expected to exhibit a CAGR of 11.5% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 4.9 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 11.50% 2030 Value Projection: US$ 10.5 Bn
Global Custom Recombinant Protein Production Services Market Share (%), By Expression System, 2023
Custom Recombinant Protein Production Services Market - IMG1

Recombinant proteins have a wide range of applications in biotechnology, research, and medicine. Custom recombinant protein production is one of the efficient techniques used in the life sciences sector that plays a major role in advanced healthcare. Recombinant proteins are developed by manipulating proteins using certain techniques. Genes are then used to encode these recombinant proteins, which are then produced in large quantities and used to make therapeutic and commercial products. Increasing government initiatives and funding in the field of life sciences is expected to boost growth of the market.

Many recombinant proteins require and provide post-translational modifications such as glycosylation, which are only available in eukaryotic, yeast, mammalian, and insect cell culture systems. HEK293-derived cell lines are used for transient protein production. Currently, most recombinant therapeutic proteins are produced in mammalian cells due to their ability to produce high-quality proteins similar in nature. In addition, many approved recombinant therapeutic proteins have been produced in E. coli due to well-characterized genetics, rapid growth, and high-yield production.

Market Dynamics

The increasing adoption of inorganic growth strategies such as acquisitions by the key players is expected to drive segment growth over the forecast period. For instance, in July 2021, Atlas Antibodies, a manufacturer of highly validated primary antibodies, acquired Evitria, a developer of transient recombinant antibody expression in Chinese hamster ovary (CHO) cells. CHO cells are the preferred expression system for recombinant therapeutic protein (RTP) production. The acquisition will combine the antibody solutions of both companies and expand their businesses.

Key features of the study:

  • This report provides an in-depth analysis of the global custom recombinant protein production services market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global custom recombinant protein production services market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include GenScript Biotech Corporation, SignalChem Biotech Inc., Crown Bioscience, Inc., BPS Bioscience Inc., Novoprotein, Applied Biological Materials (abm) Inc., Eurofins Pharma Discovery Services, Abgent (WuXi AppTec Company), OriGene Technologies, Inc., Kempbio, Inc., Trenzyme GmbH, Sino Biological Inc., Aragen Bioscience, a GVKBIO Company, LakePharma, Inc., , Proteos Inc., Icosagen AS, Novus Biological LLC, Proteogenix, Premas Biotech, ATUM, and Aldevron
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global custom recombinant protein production services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global custom recombinant protein production services market.

Custom Recombinant Protein Production Services Market Detailed Segmentation:

  • By Expression System:
    • Mammalian
    • Bacteria
    • Insect
    • Yeast
    • Others
  • By End User :
    • Research Institutes
    • Biotechnology and Pharmaceutical Companies
    • Contract Research Organizations
    • Others
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • GenScript Biotech Corporation
    • SignalChem Biotech Inc.
    • Crown Bioscience, Inc.
    • BPS Bioscience Inc.
    • Novoprotein
    • Applied Biological Materials (abm) Inc.
    • Eurofins Pharma Discovery Services
    • Abgent (WuXi AppTec Company)
    • OriGene Technologies, Inc.
    • Kempbio, Inc.
    • Trenzyme GmbH
    • Sino Biological Inc.
    • Aragen Bioscience, a GVKBIO Company
    • LakePharma, Inc.,
    • Proteos Inc.
    • Icosagen AS
    • Novus Biological LLC
    • Proteogenix
    • Premas Biotech
    • ATUM
    • Aldevron

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Expression System
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Test Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Custom Recombinant Protein Production Services Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Custom Recombinant Protein Production Services Market, By Expression System , 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Mammalian
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Bacteria
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Insect
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Yeast
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global Custom Recombinant Protein Production Services Market, By End User, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Biotechnology and Pharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Contract Research Organizations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global Custom Recombinant Protein Production Services Market, By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Expression System , 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By End User, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Expression System , 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By End User, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Expression System , 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By End User, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Expression System , 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By End User, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Expression System , 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By End User, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Expression System , 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By End User, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Company Profiles
    • GenScript Biotech Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • SignalChem Biotech Inc.
    • Crown Bioscience, Inc.
    • BPS Bioscience Inc.
    • Novoprotein
    • Applied Biological Materials (abm) Inc.
    • Eurofins Pharma Discovery Services
    • Abgent (WuXi AppTec Company)
    • Kempbio, Inc.
    • Trenzyme GmbH
    • Sino Biological Inc.
    • Aragen Bioscience, a GVKBIO Company
    • LakePharma, Inc.
    • Proteos Inc.
    • Icosagen AS
    • Novus Biological LLC
    • Proteogenix
    • Premas Biotech
    • ATUM
    • Aldevron

9. Section

  • References
  • Research Methodology
  • About us and Contact
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦